Lund-based Spago Nanomedical recently published its first interim report of the year and presented the activities from its Spagopix and Tumorad projects. BioStock talked to CEO Mats Hansen about the most important events during the quarter and about the potential of the projects.

Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:

https://www.biostock.se/en/2022/05/spago-nanomedical-on-project-potential/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/spago/r/biostock--spago-nanomedical-on-project-potential,c3558420

(c) 2022 Cision. All rights reserved., source Press Releases - English